Fulgent Genetics, Inc. FLGT
Fulgent Genetics, Inc. (Nasdaq: FLGT) is an oncology drug developer. Its lead program, FID-007, is in Phase 2 for cancers (broad range). Its next catalyst on record is FID-007: continued development efforts following end of Phase 2 meetings with FDA (date not stated).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: FID-007 — continued development efforts following end of Phase 2 meetings with FDA (date not stated). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| FID-007 | cancers | small molecule | Phase 2 |
| FID-022 | cancers | small molecule | Phase 1 |
| pre-clinical programs | cancers (various) | small molecule | Pre-clinical |
Recent results and decisions
- Nov 5, 2026started FID-022 first-in-human dose escalation study is ongoing, with dosing completed for the first four dose levels and maximum tolerated dose expected in 2H 2027.
Dosing completed for first 4 dose levels Determine maximum tolerated dose level in 2H 2027
Filing - Sep 30, 2026n/a Fulgent completed an End of Phase 2 meeting with FDA in 3Q 2026 for FID-007 in R/M HNSCC.
End of Ph2 meeting with FDA in 3Q 2026
Filing - Jun 30, 2026positive FID-007 combined with cetuximab demonstrated an objective response rate of 61.9% and median progression-free survival of 6.7 months in R/M HNSCC as of June 2026.
In an ongoing Phase 2, open-label trial and as of June 2026, FID-007 demonstratedencouraging clinical activity when combined with cetuximab in patients with R/M HNSCC.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 oncology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.